Literature DB >> 23858015

Too much of a good thing? When to stop catch-up vaccination.

David W Hutton1, Margaret L Brandeau2.   

Abstract

During the 20th century, deaths from a range of serious infectious diseases decreased dramatically due to the development of safe and effective vaccines. However, infant immunization coverage has increased only marginally since the 1960s, and many people remain susceptible to vaccine-preventable diseases. "Catch-up vaccination" for age groups beyond infancy can be an attractive and effective means of immunizing people who were missed earlier. However, as newborn vaccination rates increase, catch-up vaccination becomes less attractive: the number of susceptible people decreases, so the cost to find and vaccinate each unvaccinated person may increase; in addition, the number of infected individuals decreases, so each unvaccinated person faces a lower risk of infection. This article presents a general framework for determining the optimal time to discontinue a catch-up vaccination program. We use a cost-effectiveness framework: we consider the cost per quality-adjusted life year gained of catch-up vaccination efforts as a function of newborn immunization rates over time and consequent disease prevalence and incidence. We illustrate our results with the example of hepatitis B catch-up vaccination in China. We contrast results from a dynamic modeling approach with an approach that ignores the impact of vaccination on future disease incidence. The latter approach is likely to be simpler for decision makers to understand and implement because of lower data requirements.

Entities:  

Keywords:  Vaccine; epidemic control; hepatitis B

Mesh:

Year:  2013        PMID: 23858015      PMCID: PMC4247340          DOI: 10.1177/0272989X13493142

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  80 in total

1.  Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective.

Authors:  W J Edmunds; G F Medley; D J Nokes
Journal:  Stat Med       Date:  1999-12-15       Impact factor: 2.373

2.  Policy analysis of the use of hepatitis B, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules.

Authors:  M A Miller; L McCann
Journal:  Health Econ       Date:  2000-01       Impact factor: 3.046

Review 3.  Development of WHO guidelines on generalized cost-effectiveness analysis.

Authors:  C J Murray; D B Evans; A Acharya; R M Baltussen
Journal:  Health Econ       Date:  2000-04       Impact factor: 3.046

4.  Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience.

Authors:  M F Yuen; C C Cheng; I J Lauder; S K Lam; C G Ooi; C L Lai
Journal:  Hepatology       Date:  2000-02       Impact factor: 17.425

5.  Nationwide vaccination: a success story in Taiwan.

Authors:  K Huang; S Lin
Journal:  Vaccine       Date:  2000-02-18       Impact factor: 3.641

Review 6.  Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity.

Authors: 
Journal:  Lancet       Date:  2000-02-12       Impact factor: 79.321

7.  Review of regional measles surveillance data in the Americas, 1996-99.

Authors:  B S Hersh; G Tambini; A C Nogueira; P Carrasco; C A de Quadros
Journal:  Lancet       Date:  2000-06-03       Impact factor: 79.321

8.  Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.

Authors:  T A Lieu; G T Ray; S B Black; J C Butler; J O Klein; R F Breiman; M A Miller; H R Shinefield
Journal:  JAMA       Date:  2000-03-15       Impact factor: 56.272

9.  Comparison of two hepatitis B vaccines (GeneVac-B and Engerix-B) in healthy infants in India.

Authors:  Virbhadra Somani; B S Srikanth; M Mohan; P S Kulkarni
Journal:  Clin Vaccine Immunol       Date:  2006-06

Review 10.  Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Authors:  J Shepherd; J Jones; A Takeda; P Davidson; A Price
Journal:  Health Technol Assess       Date:  2006-08       Impact factor: 4.014

View more
  4 in total

1.  Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.

Authors:  Ashish Goyal; John M Murray
Journal:  Clin Drug Investig       Date:  2016-08       Impact factor: 2.859

2.  Creating impact with operations research in health: making room for practice in academia.

Authors:  Margaret L Brandeau
Journal:  Health Care Manag Sci       Date:  2015-05-24

3.  HIV Treatment and Prevention: A Simple Model to Determine Optimal Investment.

Authors:  Jessie L Juusola; Margaret L Brandeau
Journal:  Med Decis Making       Date:  2015-09-14       Impact factor: 2.749

Review 4.  Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature Review.

Authors:  Tom L Drake; Angela Devine; Shunmay Yeung; Nicholas P J Day; Lisa J White; Yoel Lubell
Journal:  Health Econ       Date:  2016-01-17       Impact factor: 3.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.